Vincerx Pharma (NASDAQ:VINC) Stock Rating Reaffirmed by Cantor Fitzgerald

Vincerx Pharma (NASDAQ:VINC)‘s stock had its “overweight” rating reissued by research analysts at Cantor Fitzgerald in a research note issued to investors on Tuesday, Benzinga reports.

Vincerx Pharma Trading Down 5.7 %

NASDAQ VINC opened at $1.00 on Tuesday. The company’s 50-day moving average price is $4.22 and its 200-day moving average price is $2.09. The stock has a market cap of $21.41 million, a PE ratio of -0.53 and a beta of 1.10. Vincerx Pharma has a 12 month low of $0.61 and a 12 month high of $9.37.

Institutional Inflows and Outflows

Hedge funds have recently made changes to their positions in the stock. Susquehanna International Group LLP purchased a new stake in Vincerx Pharma in the first quarter worth about $28,000. Goldman Sachs Group Inc. lifted its stake in Vincerx Pharma by 21.3% in the second quarter. Goldman Sachs Group Inc. now owns 36,126 shares of the company’s stock worth $48,000 after acquiring an additional 6,334 shares during the period. Rhumbline Advisers purchased a new stake in Vincerx Pharma in the first quarter worth about $53,000. ExodusPoint Capital Management LP purchased a new stake in Vincerx Pharma in the second quarter worth about $132,000. Finally, Walleye Capital LLC purchased a new stake in Vincerx Pharma in the second quarter worth about $176,000. 44.02% of the stock is currently owned by institutional investors.

About Vincerx Pharma

Vincerx Pharma, Inc, a clinical-stage biopharmaceutical company, researches and develops therapies to address unmet medical needs for the treatment of cancer in the United States. It is developing enitociclib, a cyclin-dependent kinase-9 inhibitor that is in Phase 1 clinical trials for treating patients with hematologic malignancies; and VIP236, a small molecule drug conjugate that is in Phase 1 clinical trials to treat solid tumors.